Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Premature ejaculation as defined by DSM-IV

Exclusion Criteria:

• History of erectile dysfunction